It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Melanoma is the deadliest skin cancer. Despite improvements in the understanding of the molecular mechanisms underlying melanoma biology and in defining new curative strategies, the therapeutic needs for this disease have not yet been fulfilled. Herein, we provide evidence that the Activating Molecule in Beclin-1-Regulated Autophagy (Ambra1) contributes to melanoma development. Indeed, we show that Ambra1 deficiency confers accelerated tumor growth and decreased overall survival in Braf/Pten-mutated mouse models of melanoma. Also, we demonstrate that Ambra1 deletion promotes melanoma aggressiveness and metastasis by increasing cell motility/invasion and activating an EMT-like process. Moreover, we show that Ambra1 deficiency in melanoma impacts extracellular matrix remodeling and induces hyperactivation of the focal adhesion kinase 1 (FAK1) signaling, whose inhibition is able to reduce cell invasion and melanoma growth. Overall, our findings identify a function for AMBRA1 as tumor suppressor in melanoma, proposing FAK1 inhibition as a therapeutic strategy for AMBRA1 low-expressing melanoma.
The absence of scaffold protein Ambra1 leads to hyperproliferation and growth in mouse models. Here the authors show that Ambra1 deficiency accelerates melanoma growth and increases metastasis in mouse models of melanoma through FAK1 hyperactivation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details













1 Melanoma Research Team, Cell Stress and Survival Unit, Center for Autophagy, Recycling and Disease (CARD), Danish Cancer Society Research Center, Copenhagen, Denmark (GRID:grid.417390.8) (ISNI:0000 0001 2175 6024)
2 University of Leuven, Lab of Translational Cell and Tissue Research, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
3 INSERM U981, Gustave Roussy Institute, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
4 Copenhagen University Hospital, National Center for Cancer Immune Therapy, Department of Oncology, Herlev, Denmark (GRID:grid.4973.9) (ISNI:0000 0004 0646 7373)
5 Redox Biology Group, Danish Cancer Society Research Center, Copenhagen, Denmark (GRID:grid.417390.8) (ISNI:0000 0001 2175 6024)
6 University of Rome Tor Vergata, Department of Biology, Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941)
7 Department of Pediatric Hematology and Oncology, Bambino Gesù Children’s Hospital, Rome, Italy (GRID:grid.414125.7) (ISNI:0000 0001 0727 6809)
8 University of Luxembourg, Life Sciences Research Unit, Belvaux, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843)
9 School of Medicine, Division of Hematology and Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)
10 Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
11 Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Oregon Health & Science University, Knight Cancer Institute, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
12 Molecular Diagnostics Group, Danish Cancer Society Research Center, Copenhagen, Denmark (GRID:grid.417390.8) (ISNI:0000 0001 2175 6024); University of Southern Denmark, Department of Cancer and Inflammation Research, Institute for Molecular Medicine, Odense, Denmark (GRID:grid.10825.3e) (ISNI:0000 0001 0728 0170)
13 Redox Biology Group, Danish Cancer Society Research Center, Copenhagen, Denmark (GRID:grid.417390.8) (ISNI:0000 0001 2175 6024); University of Rome Tor Vergata, Department of Biology, Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941); University of Copenhagen, Center for Healthy Aging, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
14 INSERM U981, Gustave Roussy Institute, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388); Université Paris-Sud, Université Paris-Saclay, Kremlin-Bicêtre, France (GRID:grid.5842.b) (ISNI:0000 0001 2171 2558); Dermato-Oncology, Gustave Roussy Cancer Campus, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
15 University of Rome Tor Vergata, Department of Biology, Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941); Department of Pediatric Hematology and Oncology, Bambino Gesù Children’s Hospital, Rome, Italy (GRID:grid.414125.7) (ISNI:0000 0001 0727 6809); Cell Stress and Survival Unit, Center for Autophagy, Recycling and Disease (CARD), Danish Cancer Society Research Center, Copenhagen, Denmark (GRID:grid.417390.8) (ISNI:0000 0001 2175 6024)